Certolizumab pegol – new option in the treatment of psoriatic arthritis
It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availab...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2014-07-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Certolizumab-pegol-new-option-in-the-treatment-of-psoriatic-arthritis,18,23171,1,1.html |
| _version_ | 1818983022370750464 |
|---|---|
| author | Maria Majdan Anna Siwiec Aleksandra Gryta |
| author_facet | Maria Majdan Anna Siwiec Aleksandra Gryta |
| author_sort | Maria Majdan |
| collection | DOAJ |
| description | It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availability of biological drugs which are TNF inhibitors. Among the first TNF inhibitors that have been used to treat PsA were etanercept, adalimumab, infliksymab. Due to primary and secondary ineffectiveness of the therapy occurring in large numbers of PsA patients investigations are going on in order to develop new, more effective, safer and more convenient methods to treat PsA. Such a new therapeutic possibility is offered by the new generation TNF inhibitor with a molecular structure different from other TNF inhibitors – certolizumab pegol (CZP).In this article the results of clinical studies concerning the application of CZP in PsA treatment are presented. |
| first_indexed | 2024-12-20T17:56:30Z |
| format | Article |
| id | doaj.art-6df24ec3a45e46999f2222ca39a4b2a0 |
| institution | Directory Open Access Journal |
| issn | 0034-6233 2084-9834 |
| language | English |
| last_indexed | 2024-12-20T17:56:30Z |
| publishDate | 2014-07-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Rheumatology |
| spelling | doaj.art-6df24ec3a45e46999f2222ca39a4b2a02022-12-21T19:30:45ZengTermedia Publishing HouseRheumatology0034-62332084-98342014-07-0152318118810.5114/reum.2014.4408823171Certolizumab pegol – new option in the treatment of psoriatic arthritisMaria MajdanAnna SiwiecAleksandra GrytaIt has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availability of biological drugs which are TNF inhibitors. Among the first TNF inhibitors that have been used to treat PsA were etanercept, adalimumab, infliksymab. Due to primary and secondary ineffectiveness of the therapy occurring in large numbers of PsA patients investigations are going on in order to develop new, more effective, safer and more convenient methods to treat PsA. Such a new therapeutic possibility is offered by the new generation TNF inhibitor with a molecular structure different from other TNF inhibitors – certolizumab pegol (CZP).In this article the results of clinical studies concerning the application of CZP in PsA treatment are presented.http://www.termedia.pl/Certolizumab-pegol-new-option-in-the-treatment-of-psoriatic-arthritis,18,23171,1,1.htmlpsoriatic arthritis certolizumab pegol treatment |
| spellingShingle | Maria Majdan Anna Siwiec Aleksandra Gryta Certolizumab pegol – new option in the treatment of psoriatic arthritis Rheumatology psoriatic arthritis certolizumab pegol treatment |
| title | Certolizumab pegol – new option in the treatment of psoriatic arthritis |
| title_full | Certolizumab pegol – new option in the treatment of psoriatic arthritis |
| title_fullStr | Certolizumab pegol – new option in the treatment of psoriatic arthritis |
| title_full_unstemmed | Certolizumab pegol – new option in the treatment of psoriatic arthritis |
| title_short | Certolizumab pegol – new option in the treatment of psoriatic arthritis |
| title_sort | certolizumab pegol new option in the treatment of psoriatic arthritis |
| topic | psoriatic arthritis certolizumab pegol treatment |
| url | http://www.termedia.pl/Certolizumab-pegol-new-option-in-the-treatment-of-psoriatic-arthritis,18,23171,1,1.html |
| work_keys_str_mv | AT mariamajdan certolizumabpegolnewoptioninthetreatmentofpsoriaticarthritis AT annasiwiec certolizumabpegolnewoptioninthetreatmentofpsoriaticarthritis AT aleksandragryta certolizumabpegolnewoptioninthetreatmentofpsoriaticarthritis |